Evaluation of Mutagenicity of Mebudipine, a New Calcium Channel Blocker

Authors

  • F Hoseini Shirazi
  • F Soleimani
  • M Mahmoudian
  • M Touhidpour
  • S Gholami
Abstract:

Mebudipine is a new dihydropyridine calcium channel blocker, synthesized in our laboratory, for treatment of hypertension. It has shown a better efficacy than other drugs in this group. For assessing the risks of this drug, certain safety tests in the preclinical stage have been performed. In this study mutagenic effect of mebudipine was evaluated using Ames assay that could assess the mutagenicity of drugs and their metabolites using liver enzymes (S-9 mix). This procedure is approved as a predictive test, with a high predictive value. Salmonella TA102 (Ames assay) was used with and without S-9 in this study. For preparing S-9 mix, rat liver enzymes induced by phenobarbital were separated in KCl 0.154 M (0.154 M), as the solvent. Mebudipine was dissolved in polyethylenglycol 400. Mutagenicity test was performed in 6 doses from 39 µg to 1250 µg per every plate, in the presence and absence of the S-9 mix. The positive control sodium azide was dissolved in a dose of 5 µg/plate dissolved in polyethylenglycol 400 and negative control was polyethylenglycol 400 with no added agent. The colony counts of all doses in plates with S-9 were between 200-400 and in plates without S9 was between100-300. The colony counts in both states (with and without S-9) of all doses were in the range suggested by Ames assay for the safe drugs and were different from the positive control groups and equal to the negative controls. Mebudipine and its metabolites were not found to be mutagen on Salmonella TA102, based on Ames assay.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

evaluation of mutagenicity of mebudipine, a new calcium channel blocker

mebudipine is a new dihydropyridine calcium channel blocker, synthesized in our laboratory, for treatment of hypertension. it has shown a better efficacy than other drugs in this group. for assessing the risks of this drug, certain safety tests in the preclinical stage have been performed. in this study mutagenic effect of mebudipine was evaluated using ames assay that could assess the mutageni...

full text

Hyperinsulinemic Euglycemia and Intravenous Lipid Emulsion Treatments for Calcium Channel Blocker and Beta Blocker Poisoning: A Report of Two Cases

Poisoning with calcium channel blockers and beta blockers are associated with high mortality and morbidity rates, especially in children. Treatment of poisoning with these drugs includes administration of atropine, glucagon, calcium and inotropic agents as clinically needed; and newer approaches like hyperinsulinemic euglycemia and intravenous lipid emulsion therapies. We herein present two ref...

full text

Calcium-Channel Blocker Overdose

1522-8401/$ see fro doi:10.1016/j.cpem.2 Department of Eme Children’s Hospit RI 02903, USA. Reprint requests and Department of E Children’s Hospit RI 02903, USA. Calcium-channel blockers (CCB) were first developed in the 1960s. Since then, the list of formulations and variety of uses has increased significantly. Unfortunately, toxic exposures to CCBs have also increased since their debut. This ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume Volume 9  issue Number 1

pages  49- 53

publication date 2010-11-20

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023